

# Nephrology Drugs Market Poised for Growth, Expected to Reach \$21.53 Billion by 2028

The Business Research Company has updated all its market reports with the latest information for the year 2024, projecting trends and forecasts until 2033

LONDON, GREATER LONDON, UK, June 17, 2024 /EINPresswire.com/ -- The nephrology drugs market has shown robust growth, expanding from \$16.18 billion in 2023 to \$17.08 billion in 2024,



at a CAGR of 5.6%. It will grow to \$21.53 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. This growth is attributed to factors such as the rising prevalence of chronic kidney diseases (CKD), advancements in drug development, increasing awareness and diagnosis, government initiatives, and the growing incidence of diabetes.



The Business Research
Company has updated all its
market reports with the
latest information for the
year 2024, projecting trends
and forecasts until 2033"

The Business Research
Company

Rising Prevalence of Chronic Kidney Disease Drives Market Growth

The increasing prevalence of chronic kidney disease (CKD) is a key driver for the nephrology drugs market. CKD refers to the gradual loss of kidney function over time, leading to the accumulation of waste products in the body. Nephrology drugs play a crucial role in managing CKD, enhancing kidney function, and slowing disease progression. According to the Centers for Disease Control and Prevention (CDC), over 37 million people in the US

were diagnosed with CKD, with a higher prevalence among individuals aged 65 years and older. Similarly, in Canada, 4 million people suffer from kidney diseases, with diabetes being a leading cause of kidney failure. These statistics underscore the growing demand for nephrology drugs worldwide.

Explore comprehensive insights into the nephrology drugs market with a detailed sample report: <a href="https://www.thebusinessresearchcompany.com/sample\_request?id=10076&type=smp">https://www.thebusinessresearchcompany.com/sample\_request?id=10076&type=smp</a>

Major companies in the nephrology drugs market include AstraZeneca PLC, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc these companies are focused on developing new therapies and treatments to cater to the increasing healthcare needs. For instance, Jardiance (empagliflozin), approved by the U.S. Food and Drug Administration, represents a significant advancement in managing type 2 diabetes mellitus and potentially lowering the risk of kidney disease progression and cardiovascular death. This underscores a trend towards personalized treatment approaches and precision medicine in nephrology.

# Segments:

report

- By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs
- By Route Of Administration: Oral, Parenteral, Other Route Of Administration
- By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
- By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Geographical Insights: North America Leads, Europe Shows Strong Growth North America emerged as the largest region in the nephrology drugs market in 2024, driven by high healthcare expenditures and advanced healthcare infrastructure. Europe is anticipated to exhibit significant growth, highlighting increasing healthcare awareness and supportive government policies.

Access the complete report for an in-depth analysis of the nephrology drugs market: <a href="https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report">https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report</a>

Nephrology Drugs Global Market Report 2024 from TBRC covers the following information:

- Market size date for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Nephrology Drugs Global Market Report 2024 by <u>The Business Research Company</u> is the most comprehensive report that provides insights on nephrology drugs market size, nephrology drugs market drivers and trends, nephrology drugs market major players, competitors' revenues, market positioning, and market growth across geographies. The nephrology drugs market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
Drug Delivery Devices Global Market Report 2024
<a href="https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-">https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-</a>

Drugs For Hormonal Replacement Therapy Global Market Report 2024 <a href="https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report">https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report</a>

Nephrology Drugs Global Market Report 2024 <a href="https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report">https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report</a>

# About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

# Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

### **Contact Information**

The Business Research Company

Europe: +44 207 1930 708 Asia: +91 8897263534 Americas: +1 315 623 0293

Email: info@tbrc.info

### Check out our:

LinkedIn: <a href="https://in.linkedin.com/company/the-business-research-company">https://in.linkedin.com/company/the-business-research-company</a>

Twitter: https://twitter.com/tbrc\_info

Facebook: <a href="https://www.facebook.com/TheBusinessResearchCompany">https://www.facebook.com/TheBusinessResearchCompany</a>
YouTube: <a href="https://www.youtube.com/channel/UC24">https://www.youtube.com/channel/UC24</a> fl0rV8cR5DxlCpgmvFQ

Blog: <a href="https://blog.tbrc.info/">https://blog.tbrc.info/</a>

Healthcare Blog: <a href="https://healthcareresearchreports.com/">https://healthcareresearchreports.com/</a>

Global Market Model: <a href="https://www.thebusinessresearchcompany.com/global-market-model">https://www.thebusinessresearchcompany.com/global-market-model</a>

### Oliver Guirdham

The Business Research Company +44 20 7193 0708

info@tbrc.info

Visit us on social media:

Facebook

## LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/720571142

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.